ACMD

Advisory Council on the Misuse of Drugs

**Advisory Council on the Misuse of Drugs (ACMD)**

**Evidence for a report on the implementation and provision of naloxone**

The ACMD is undertaking a review of evidence on both the implementation and the impact of naloxone programmes in the UK since 2012.

Please use this template to submit written evidence (with appropriate referencing) on the points of interest in the table below. There is no word limit, but we would ask that written paragraphs are kept concise.

Please return to [robert.wolstenholme@phe.gov.uk](mailto:robert.wolstenholme@phe.gov.uk) and [acmd@homeoffice.gov.uk](mailto:acmd@homeoffice.gov.uk)

The deadline for written submissions is Tuesday 30 June 2020. The ACMD expects to provide a final report with recommendations to government by the end of 2020.

**Points of interest to the ACMD**

|  |  |
| --- | --- |
| Prevalence and nature of naloxone provision, carriage and use |  |
| Evidence of effectiveness of naloxone |  |
| Evidence of who is administering naloxone (police, voluntary services, etc.) |  |
| Barriers to uptake of naloxone (both intramuscular and intranasal naloxone) |  |
| Evidence of collaborative approaches to provision |  |
| Case studies of note |  |
| *If you have evidence and practice examples to share which don’t fit into one of the categories above, please add detail here* |  |